Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abbott Medical Devices
With
Japanese society of Congenital Interventional Cardiology
The Surveillance will be conducted per the standards required by the Ministry of Health, Labour and Welfare (MHLW) and in the standards for post-marketing surveillances and studies \[except for those defined in the Ministerial Ordinance on Good Clinical Practice for Medical Devices (MHLW Ordinance No. 36, 2005)\] based on Paragraph 4, Article 23-2-9 (including application mutatis mutandis per Article 23-2-19 of Revised PAL) of the Law on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, etc. (Law No. 145, 1960, hereinafter referred to as "Revised PAL") by the Marketing Authorization Holder or accredited foreign manufacturer of a medical device defined in Paragraph 1, Article 23-2-5 of Revised PAL.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The device is used to percutaneously close the PDA of a patient who meets all of the following:
PDA ≤4 mm in diameter
PDA ≥3 mm in length
Weight ≥700 g
You may not be if
Age \<3 days
Coarctation of the aorta
Left pulmonary artery stenosis
Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension
Thrombus in the implant site, or sign of venous thrombus in a vessel in which the occluder is inserted and delivered
Endocarditis, or infection that can cause bacteremia